FIORINAL W/CODEINE
LOE ApproachingNDAORALCAPSULE
Approved
Oct 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIORINAL W/CODEINE is a combination analgesic capsule containing butalbital, aspirin, caffeine, and codeine phosphate indicated for tension headache relief. The product combines a barbiturate, NSAID, stimulant, and opioid to address pain through multiple mechanisms. It is an oral small-molecule formulation approved over three decades ago.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FIORINAL W/CODEINE offers limited growth trajectory as the product approaches loss of exclusivity with zero linked job openings. Career opportunities are concentrated in defensive commercial roles focused on market protection and cost management rather than expansion.
Brand ManagerProduct Manager
Worked on FIORINAL W/CODEINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.